<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="133825">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359566</url>
  </required_header>
  <id_info>
    <org_study_id>XP-B-089</org_study_id>
    <nct_id>NCT01359566</nct_id>
    <nct_alias>NCT01360489</nct_alias>
  </id_info>
  <brief_title>Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indivior Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indivior Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of three doses of XP19986 (arbaclofen placarbil) compared to
      placebo for the treatment of spasticity in subjects with multiple sclerosis (MS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Maximum Ashworth Scale score (6 hour post-dose time point)</measure>
    <time_frame>10-weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Global Impression of Change (PGIC) score</measure>
    <time_frame>10-weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the overall Modified PRISM score</measure>
    <time_frame>Weeks 4, 6, 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weekly average severity of pain score associated with muscle spasm.</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weekly average VAS score of sleep quality</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">228</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Arbaclofen placarbil 15 mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arbaclofen placarbil (XP19986 SR4) 15 mg every morning and every evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arbaclofen placarbil 30 mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arbaclofen placarbil (XP19986 SR4) 30 mg every morning and every evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arbaclofen placarbil 45 mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arbaclofen placarbil (XP19986 SR4) 45 mg every morning and every evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo every morning and every evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arbaclofen placarbil 15 mg BID</intervention_name>
    <description>arbaclofen placarbil 15 mg BID</description>
    <arm_group_label>Arbaclofen placarbil 15 mg BID</arm_group_label>
    <other_name>XP19986 SR4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for arbaclofen placarbil 15, 30 and 45 mg BID</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arbaclofen placarbil 30 mg BID</intervention_name>
    <description>arbaclofen placarbil 30 mg BID</description>
    <arm_group_label>Arbaclofen placarbil 30 mg BID</arm_group_label>
    <other_name>XP19986 SR4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arbaclofen placarbil 45 mg BID</intervention_name>
    <description>arbaclofen placarbil 45 mg BID</description>
    <arm_group_label>Arbaclofen placarbil 45 mg BID</arm_group_label>
    <other_name>XP19986 SR4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has multiple sclerosis (MS) based on Poser or McDonald Criteria (all subtypes of MS
             will be accepted, including relapsing remitting, primary or secondary progressive, if
             disease is stable per exclusion criteria).

          2. Maximum Ashworth Score Scale score of ≥ 2 in at least one of the following muscle
             groups on either side of the body: hip abductors/adductors, knee flexors/extensors,
             ankle flexors/extensors.

          3. Expanded Disability Status Scale (EDSS) rating between 3.0-8.0 inclusive.

          4. If a subject is on disease modifying MS treatment, the dosage, frequency, and route
             of administration must be stable for at least 30 days before screening and is
             expected to be stable throughout the study.

          5. Spasticity Disability Rating of 2 or higher at Baseline.

          6. Willing to discontinue and refrain from using for the duration of the study drugs for
             the treatment of spasticity or likely to affect spasticity (including, but not
             limited to, baclofen, tizanidine, diazepam, clonazepam, metaxalone, dantrolene,
             cyclobenzaprine, carisoprodol, clonidine, vigabatrin, valproic acid and cannabis).

        Exclusion Criteria:

          1. Spasticity due to neurological disorder other than MS or other conditions that may
             confound the assessment of spasticity.

          2. Subject has clinically evident muscle contractures resulting in irreversible
             spasticity in lower extremities.

          3. Subjects who have suffered an acute relapse of MS (as determined by the Investigator)
             within 90 days prior to Screening, or have had more than 1 relapse within the year
             prior to Screening

          4. Botulinum toxin injection within 6 months of Screening or has current residual
             associated side effects at Screening.

          5. Subjects receiving concomitant medication from more than one of the following three
             drug classes: (Antiepileptic drugs, Tricyclic anti-depressants and Opioids)

          6. Subjects on the following medications, at doses above the specified limits, are
             excluded if they cannot maintain a level within these limits

               -  Gabapentin ≤ 1800 mg per day or pregabalin ≤ 150 mg per day

               -  Amitriptyline ≤ 75 mg per day or nortriptyline ≤ 75 mg per day

               -  Opioids ≤ 30 mg morphine equivalents per day.

          7. Evidence of unstable or severe systemic illness, including but not limited to:
             Cardiovascular disease (e.g., chronic ventricular arrhythmia, unstable angina or
             CHF), respiratory disease (e.g., sleep apnea, COPD requiring oxygen therapy or
             hospitalization in last year), endocrine disease, hepatic disease (e.g., chronic
             active hepatitis), renal disease, or immunodeficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Indivior Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Lake Barrington</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Bingham Farms</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Patchogue</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Vienna</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XenoPort Clinical Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 28, 2015</lastchanged_date>
  <firstreceived_date>May 22, 2011</firstreceived_date>
  <firstreceived_results_disposition_date>December 28, 2015</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arbaclofen placarbil</mesh_term>
    <mesh_term>Baclofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
